Centene Reshapes Medicare Advantage Business for 2027 Amid Rising Costs

Centene Corporation (CNC) is restructuring its Medicare Advantage (MA) business for 2027 in response to rising costs and challenging market conditions. The company's Wellcare unit will discontinue certain MA offerings and reduce its presence in several counties, focusing on a more disciplined strategy. Specifically, Centene is pulling standard MA plans from 344 counties and exiting Hawaii, Oklahoma, and Tennessee entirely. Wellcare is also scaling back its plan lineup, particularly standard MA offerings, while maintaining a stronger focus on Special Needs Plans.

The adjustments come as the MA industry faces elevated healthcare utilization and pressure on plan economics. The Centers for Medicare & Medicaid Services projects a 16.5% decline in weighted average monthly MA premiums for 2027, with enrollment expected to reach 34 million. Insurers are adapting by modifying benefits, networks, and geographic coverage to manage medical costs and maintain profitability. Centene's large standalone Part D platform offers an alternative channel to serve Medicare beneficiaries outside traditional MA.

Centene's strategy could yield mixed results. Reducing exposure to less attractive markets may improve operating performance by concentrating resources on more profitable products and regions. However, a smaller MA footprint could limit potential membership growth. The company is placing greater emphasis on dual-eligible members, who make up about 40% of Wellcare's MA membership, with D-SNP products representing nearly half of its 2027 MA offerings.

Competitors like UnitedHealth Group (UNH) and Humana (HUM) are also refining their MA footprints. UnitedHealth is pulling standard plans from 140 counties while adding more Special Needs Plans, and Humana plans to exit 57 counties and Minnesota for 2027, reducing certain PPO offerings. Both companies are adopting a more selective approach to MA growth.

From a financial perspective, Centene's shares have surged 56.3% year-to-date, outpacing the industry's 16.7% growth. The company trades at a forward price-to-earnings ratio of 12.28, below the industry average of 15.20. The Zacks Consensus Estimate for Centene's 2026 earnings is $4.89 per share, implying 135.1% growth from the previous year.